RS66
NVO
News Desk
Market & Ranked Stocks News
Follow the latest RS articles, monitor market headlines, and quickly jump from a story into the stock page driving the move.
Coverage
Live Feed
Fresh market headlines as articles publish
Focus
RS + Market
Internal analysis alongside external headlines
Filter Feed
Find news by symbol
Narrow the full feed to one company ticker when you want a focused stream.
39 total articles in the current feed
RS Articles
Original Ranked Stocks analysis and rewrites
RS66
NVO
Recent Market News
External headlines and linked RS articles
RS66
NVO
ExternalZacks Investment Research•8h ago•NVO
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
Open original article →
RS66
NVO
RS Linked14h ago•NVO
Novo Nordisk: The Undervalued Comeback in the World's Fastest-Growing Drug Market
Read article →
RS66
NVO
ExternalGlobeNewsWire•15h ago•NVO
Articles of Association for Novo Nordisk A/S 2026
Open original article →
RS66
NVO
ExternalReuters•1d ago•NVO
US FDA approves Novo's insulin injection for type 2 diabetes
Open original article →
RS66
NVO
RS Linked1d ago•NVO
Novo Nordisk Secures Landmark US Approval for Awiqli®, First Once-Weekly Basal Insulin
Read article →
RS66
NVO
ExternalZacks Investment Research•2d ago•NVO
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
Open original article →
RS66
NVO
ExternalZacks Investment Research•2d ago•NVO
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Open original article →
RS66
NVO
RS Linked2d ago•NVO
Wegovy gets even cheaper in South Africa as Novo Nordisk battles Eli Lilly
Read article →
RS66
NVO
ExternalThe Motley Fool•Mar 20, 2026•NVO
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
Open original article →
RS66
NVO
ExternalReuters•Mar 20, 2026•NVO
China expresses hopes over Novo Nordisk's presence in market
Open original article →
RS66
NVO
ExternalMarket Watch•Mar 19, 2026•NVO
A high dose of Wegovy helped people lose 21% of their weight. It was just approved.
Open original article →
RS66
NVO
ExternalBenzinga•Mar 19, 2026•NVO
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
Open original article →
RS66
NVO
ExternalWSJ•Mar 19, 2026•NVO
Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
Open original article →
RS66
NVO
ExternalCNBC•Mar 19, 2026•NVO
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
Open original article →
RS66
NVO
ExternalReuters•Mar 19, 2026•NVO
US FDA approves higher dose of Wegovy
Open original article →
RS66
NVO
ExternalGlobeNewsWire•Mar 19, 2026•NVO
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Open original article →
RS66
NVO
ExternalReuters•Mar 19, 2026•NVO
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
Open original article →
RS66
NVO
ExternalZacks Investment Research•Mar 18, 2026•NVO
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
Open original article →
RS66
NVO
ExternalZacks Investment Research•Mar 17, 2026•NVO
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Open original article →
RS66
NVO
ExternalGlobeNewsWire•Mar 17, 2026•NVO
Novo Nordisk A/S Investigated by the Portnoy Law Firm
Open original article →
Page 1 of 2 • 39 articles